Corvus Pharmaceuticals Stock Price on November 22, 2024
| CRVS Stock | USD 8.93 0.02 0.22% |
Below is the normalized historical share price chart for Corvus Pharmaceuticals extending back to March 23, 2016. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Corvus Pharmaceuticals stands at 8.93, as last reported on the 26th of November, with the highest price reaching 9.35 and the lowest price hitting 8.87 during the day.
If you're considering investing in Corvus Stock, it is important to understand the factors that can impact its price. Corvus Pharmaceuticals is slightly risky given 3 months investment horizon. Corvus Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.27, which signifies that the company had a 0.27% return per unit of risk over the last 3 months. We were able to interpolate and analyze data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.36% are justified by taking the suggested risk. Use Corvus Pharmaceuticals Mean Deviation of 3.63, risk adjusted performance of 0.2003, and Downside Deviation of 4.05 to evaluate company specific risk that cannot be diversified away.
At this time, Corvus Pharmaceuticals' Total Stockholder Equity is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 68.5 M in 2024, whereas Other Stockholder Equity is likely to drop slightly above 230.8 M in 2024. . At this time, Corvus Pharmaceuticals' Price Book Value Ratio is comparatively stable compared to the past year. Price Earnings To Growth Ratio is likely to gain to 0.07 in 2024, whereas Price To Operating Cash Flows Ratio is likely to drop (3.71) in 2024. Corvus Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 23rd of March 2016 | 200 Day MA 3.5988 | 50 Day MA 7.2182 | Beta 1.044 |
Corvus |
Sharpe Ratio = 0.2748
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | CRVS | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.95 actual daily | 44 56% of assets are more volatile |
Expected Return
| 1.36 actual daily | 27 73% of assets have higher returns |
Risk-Adjusted Return
| 0.27 actual daily | 21 79% of assets perform better |
Based on monthly moving average Corvus Pharmaceuticals is performing at about 21% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Corvus Pharmaceuticals by adding it to a well-diversified portfolio.
Price Book 46.242 | Book Value 0.789 | Enterprise Value 532.5 M | Enterprise Value Ebitda 0.3557 | Shares Float 38 M |
Related Headline
Inozyme Pharma Headline on 22nd of November 2024
Acquisition by Sullivan Lynne Marie of 9367 shares of Inozym... by Sullivan Lynne Marie
Filed transaction by Inozyme Pharma Director . Grant, award or other acquisition pursuant to Rule 16b-3
Corvus Pharmaceuticals Valuation on November 22, 2024
It is possible to determine the worth of Corvus Pharmaceuticals on a given historical date. On November 22, 2024 Corvus was worth 8.95 at the beginning of the trading date compared to the closed value of 8.95. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Corvus Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Corvus Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Corvus Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Corvus Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 8.24 | 9.05 | 8.04 | 8.94 | 820,768 | |
11/22/2024 | 8.95 | 9.19 | 8.79 | 8.95 | 1,208,881 |
| 9.07 | 9.35 | 8.87 | 8.93 | 712,478 |
| Backtest Corvus Pharmaceuticals | | | Corvus Pharmaceuticals History | | | Corvus Pharmaceuticals Valuation | Previous | Next |
Corvus Pharmaceuticals Trading Date Momentum on November 22, 2024
| On November 25 2024 Corvus Pharmaceuticals was traded for 8.93 at the closing time. The top price for the day was 9.35 and the lowest listed price was 8.87 . The trading volume for the day was 712.5 K. The trading history from November 25, 2024 was a factor to the next trading day price decrease. The overall trading delta against the next closing price was 0.22% . The overall trading delta against the current closing price is 1.34% . |
Corvus Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Corvus Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Corvus Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Corvus financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Corvus Pharmaceuticals Stock history
Corvus Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Corvus is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Corvus Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Corvus Pharmaceuticals stock prices may prove useful in developing a viable investing in Corvus Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 48 M | 30.7 M | |
| Net Loss | -37.2 M | -39 M |
Corvus Pharmaceuticals Stock Technical Analysis
Corvus Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Corvus Pharmaceuticals Period Price Range
Low | November 26, 2024
| High |
0.00 | 0.00 |
Corvus Pharmaceuticals cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Corvus Pharmaceuticals November 26, 2024 Market Strength
Market strength indicators help investors to evaluate how Corvus Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Corvus Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Corvus Pharmaceuticals stock market strength indicators, traders can identify Corvus Pharmaceuticals entry and exit signals to maximize returns
Corvus Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Corvus Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Corvus Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Corvus to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.2003 | |||
| Jensen Alpha | 1.03 | |||
| Total Risk Alpha | 0.459 | |||
| Sortino Ratio | 0.2714 | |||
| Treynor Ratio | 0.7688 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Corvus Stock Analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.